Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome
– Global, pivotal Phase 3 study will evaluate efficacy and safety of zorevunersen compared to sham over a 52-week treatment period –
What is the anticipated impact on Biogen’s earnings guidance and future cash flow projections if the trial succeeds?
What are the competitive landscape and pipeline of other companies targeting Dravet syndrome, and how might this trial affect Biogen’s competitive positioning?
What are the reimbursement and pricing expectations for a disease‑modifying therapy in a rare, pediatric seizure disorder?
27 days ago